

Could DLL3-Targeted Therapies Revolutionize Small Cell Lung Cancer Treatment?
Small cell lung cancer (SCLC) presents significant therapeutic challenges due to its aggressive nature and poor prognosis. Delta-like ligand 3 (DLL3) emerges as a critical biomarker and therapeutic target, given its high expression in SCLC and limited presence in normal tissues. Explore DLL3’s role in SCLC and its potential to reshape treatment strategies. The Role […]
3 min read